title: Combination therapy and new types of agents for pulmonary arterial hypertension.
abstract: This review assesses the available evidence supporting the use of drug combinations for the management of the various forms of pulmonary arterial hypertension (PAH). Ongoing and forthcoming randomized trials evaluating this strategy are also highlighted. Furthermore, new types of agents to treat PAH in the future are explored.
authors.affiliation: Department of Respiratory Medicine, Mater Misericordiae University Hospital, University College Dublin, Eccles Street, Dublin 7, Ireland.
authors.forename: Dermot S
authors.initials: DS
authors.lastname: O'Callaghan
authors.forename: Dermot
authors.initials: D
authors.lastname: O'Callaghan
authors.forename: Sean P
authors.initials: SP
authors.lastname: Gaine
mesh_terms: D053607:Adrenomedullin / Q000502:physiology; D042683:Angiopoietin-1 / Q000502:physiology; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001549:Benzamides; D000077300:Bosentan; D004359:Drug Therapy, Combination; D015777:Eicosanoids / Q000494:pharmacology / Q000627:therapeutic use*; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D000068877:Imatinib Mesylate; D047908:Intracellular Signaling Peptides and Proteins / Q000502:physiology; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011453:Prostaglandins / Q000627:therapeutic use; D017346:Protein Serine-Threonine Kinases / Q000502:physiology; D011687:Purines / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology; D012701:Serotonin / Q000502:physiology; D050486:Serotonin Plasma Membrane Transport Proteins / Q000502:physiology; D000068677:Sildenafil Citrate; D013449:Sulfonamides / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use; D014660:Vasoactive Intestinal Peptide / Q000502:physiology; D014665:Vasodilator Agents / Q000627:therapeutic use; D054460:rho-Associated Kinases
chemical_list: D042683:Angiopoietin-1; D000959:Antihypertensive Agents; D001549:Benzamides; D015777:Eicosanoids; D047908:Intracellular Signaling Peptides and Proteins; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D011453:Prostaglandins; D011687:Purines; D011743:Pyrimidines; C493230:SLC6A4 protein, human; D050486:Serotonin Plasma Membrane Transport Proteins; D013449:Sulfonamides; D013450:Sulfones; D014665:Vasodilator Agents; D053607:Adrenomedullin; D012701:Serotonin; C048081:beraprost; D014660:Vasoactive Intestinal Peptide; D000068877:Imatinib Mesylate; D000068677:Sildenafil Citrate; D011464:Epoprostenol; D017346:Protein Serine-Threonine Kinases; D054460:rho-Associated Kinases; D000077300:Bosentan